Search research articles
Contact Us
Filters
Showing results (91-100 of 164) with videos related to
Page
of 17
Sort By:
Annals of Clinical and Translational Neurology
|
May 16, 2018
Seronegative antibody-mediated neurology after immune checkpoint inhibitors
Robert Wilson, David A Menassa, Alexander J Davies, et al.
Blood Advances
|
August 30, 2024
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Amitkumar Mehta, Leslie Popplewell, Graham P Collins, et al.
British Journal of Haematology
|
February 22, 2022
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline
George A Follows, Sally F Barrington, Kaljit S Bhuller, et al.
Scientific American
|
August 28, 2009
The start of everything
George Musser, Ricki Rusting, Kate Wong, et al.
Journal of Hematology & Oncology
|
October 31, 2021
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Michael Wang, Radhakrishnan Ramchandren, Robert Chen, et al.
Trials
|
November 11, 2018
RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
Sean H Lim, Kim M Linton, Graham P Collins, et al.
British Journal of Haematology
|
November 24, 2018
Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies
Charlotte K Brierley, Francesca M Jones, Katharine Hanlon, et al.
BMC Cancer
|
July 24, 2021
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma
Stephen W Booth, Toby A Eyre, John Whittaker, et al.
Blood Advances
|
September 18, 2024
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Joseph E Maakaron, Adam Asch, Leslie Popplewell, et al.
Frontiers in Pharmacology
|
November 16, 2020
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO
Pushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Page
of 17
Search research articles
Search
Showing results (91-100 of 164) with videos related to
Sort By:
Page
of 17
Annals of Clinical and Translational Neurology
|
May 16, 2018
Seronegative antibody-mediated neurology after immune checkpoint inhibitors
Robert Wilson, David A Menassa, Alexander J Davies, et al.
Blood Advances
|
August 30, 2024
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Amitkumar Mehta, Leslie Popplewell, Graham P Collins, et al.
British Journal of Haematology
|
February 22, 2022
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline
George A Follows, Sally F Barrington, Kaljit S Bhuller, et al.
Scientific American
|
August 28, 2009
The start of everything
George Musser, Ricki Rusting, Kate Wong, et al.
Journal of Hematology & Oncology
|
October 31, 2021
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Michael Wang, Radhakrishnan Ramchandren, Robert Chen, et al.
Trials
|
November 11, 2018
RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
Sean H Lim, Kim M Linton, Graham P Collins, et al.
British Journal of Haematology
|
November 24, 2018
Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies
Charlotte K Brierley, Francesca M Jones, Katharine Hanlon, et al.
BMC Cancer
|
July 24, 2021
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma
Stephen W Booth, Toby A Eyre, John Whittaker, et al.
Blood Advances
|
September 18, 2024
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Joseph E Maakaron, Adam Asch, Leslie Popplewell, et al.
Frontiers in Pharmacology
|
November 16, 2020
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO
Pushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Page
of 17